At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CAI Caris Life Sciences, Inc.
Market Closed 05-29 16:00:00 EDT
16.72
+0.05
+0.30%
盘后16.90
+0.18+1.08%
19:33 EDT
High17.08Low16.58Vol2.19M
Open16.78D1 Closing16.67Amplitude2.99%
Mkt Cap4.72BTradable Cap1.54BTotal Shares282.15M
T/O36.56MT/O Rate2.38%Tradable Shares91.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Caris studies MSH3 loss impact on immune checkpoint outcomes across cancers at ASCO 2026
Reuters  ·  05-22
Caris studies MSH3 loss impact on immune checkpoint outcomes across cancers at ASCO 2026
Cloud AI Update - CAI Boosts Multicloud Integration With AWS And Microsoft Partnerships
Simply Wall St.  ·  05-22
Cloud AI Update - CAI Boosts Multicloud Integration With AWS And Microsoft Partnerships
CAI Corp Reports Unaudited Net Asset Value of HK$0.14 Per Share
TIPRANKS  ·  05-15
CAI Corp Reports Unaudited Net Asset Value of HK$0.14 Per Share
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)
TIPRANKS  ·  05-14
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)
Caris Life Sciences Director Makes Bold Insider Move With Major Stock Purchase
TIPRANKS  ·  05-13
Caris Life Sciences Director Makes Bold Insider Move With Major Stock Purchase
Stock Track | Caris Life Sciences Soars 5.08% Intraday on Director Share Purchase and Analyst Rating
Stock Track  ·  05-12
Stock Track | Caris Life Sciences Soars 5.08% Intraday on Director Share Purchase and Analyst Rating
Caris director Jeff L Vacirca acquires 31,050 shares for $501,426.95
Reuters  ·  05-12
Caris director Jeff L Vacirca acquires 31,050 shares for $501,426.95
Caris Life Sciences, Inc. (CAI) Gets a Hold from Piper Sandler
TIPRANKS  ·  05-12
Caris Life Sciences, Inc. (CAI) Gets a Hold from Piper Sandler
Caris Life Sciences announces publication of study on measuring TMB using WES
TIPRANKS  ·  05-12
Caris Life Sciences announces publication of study on measuring TMB using WES
Caris study finds whole exome TMB predicts pembrolizumab survival better than gene panels
Reuters  ·  05-12
Caris study finds whole exome TMB predicts pembrolizumab survival better than gene panels
Guggenheim Sticks to Their Buy Rating for Caris Life Sciences, Inc. (CAI)
TIPRANKS  ·  05-11
Guggenheim Sticks to Their Buy Rating for Caris Life Sciences, Inc. (CAI)
Caris Life Sciences submits application to NYSDOH for Caris Assure testing
TIPRANKS  ·  05-09
Caris Life Sciences submits application to NYSDOH for Caris Assure testing
Caris Life Sciences Submits Application for Molecular Profiling Test in New York State
MT Newswires Live  ·  05-09
Caris Life Sciences Submits Application for Molecular Profiling Test in New York State
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization
THOMSON REUTERS  ·  05-09
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization
Caris submits NY health department review application for Caris Assure blood test authorization
Reuters  ·  05-09
Caris submits NY health department review application for Caris Assure blood test authorization
Stock Track | Caris Life Sciences Plummets 15.32% Intraday Despite Earnings Beat on Quarterly Loss and Analyst Estimate Revisions
Stock Track  ·  05-08
Stock Track | Caris Life Sciences Plummets 15.32% Intraday Despite Earnings Beat on Quarterly Loss and Analyst Estimate Revisions
Caris Life Sciences, Inc. (CAI) Gets a Hold from Piper Sandler
TIPRANKS  ·  05-08
Caris Life Sciences, Inc. (CAI) Gets a Hold from Piper Sandler
Guggenheim Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)
TIPRANKS  ·  05-08
Guggenheim Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)
Caris Life Sciences price target lowered to $28 from $35 at Citi
TIPRANKS  ·  05-08
Caris Life Sciences price target lowered to $28 from $35 at Citi
Caris Life Sciences Is Maintained at Buy by BTIG
Dow Jones  ·  05-08
Caris Life Sciences Is Maintained at Buy by BTIG

Introduction

Company Name.
Caris Life Sciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Caris Life Sciences, Inc. is a leading patient-centered next-generation artificial intelligence technology biology company and precision medicine pioneer. It develops and commercializes innovative solutions to transform health care through the large-scale use of comprehensive molecular information and AI/ML algorithms. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology and serving the clinical, academic and biopharmaceutical markets.
Issue price:
--